Branded Legacy, Inc. Advances Revolutionary Intranasal Drug Delivery with Unitary Device Mold Development

Rhea-AI Summary

Branded Legacy (OTC:BLEG) announced on October 27, 2025 that subsidiary BioLegacy Evaluative Group initiated engineering and development of a unitary device mold for its air-driven intranasal drug delivery platform.

The milestone advances scalable production of a single-use device intended for rapid, consistent delivery of therapeutics, including an inhaled naloxone program, and aligns with the company’s User Requirements Specification (URS). The work follows a provisional patent filing in September 2025 and complements a GMP-compliant manufacturing facility opened September 23, 2025 in Vancouver to support high-volume, cost-effective manufacturing for global pharmaceutical standards.

Positive

• Unitary mold development initiated on October 27, 2025
• Provisional patent filed in September 2025 for the air-driven intranasal device
• GMP facility opened on September 23, 2025 in Vancouver to enhance production capabilities

Negative

• Patent status is provisional only as of September 2025 and not yet granted

Pioneering Precision Engineering to Transform Global Therapeutics Delivery

VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC:BLEG), a leader in innovative addiction treatment and harm reduction solutions, today announced that its subsidiary, BioLegacy Evaluative Group Inc., has initiated engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform. This milestone marks a significant step toward scalable production of its groundbreaking single-use device, designed to deliver rapid, consistent, and reliable therapeutics, including its flagship inhaled naloxone program.

The unitary device mold defines the form and function of the innovative air-driven system, ensuring precision and scalability in alignment with the company’s rigorous User Requirements Specification (URS). This development paves the way for high-volume, cost-effective manufacturing to meet global pharmaceutical standards.

“This is a key technical milestone that bridges concept to commercial manufacturing,” said Mark O’Connor, Product Development Manager at BioLegacy Evaluative Group. “By advancing the mold design in accordance with our URS framework, we’re ensuring that every production step from material selection to form and function meets the standards required for global pharmaceutical deployment.”

This achievement builds on Branded Legacy’s recent momentum, including the September 2025 filing of a provisional patent for its Air-Driven Unitary Intranasal Drug Delivery Device for Stable and Reconstitutable Medicaments, as announced on GlobeNewswire. It also complements the company’s newly established GMP-compliant manufacturing facility in Vancouver, unveiled on September 23, 2025, which enhances production capabilities for life-saving therapies. Together, these advancements position Branded Legacy to address critical public health challenges, such as the opioid crisis, with affordable and accessible solutions.

Watch a short video of Dr. Mark O’Connor outlining the mold engineering process on our X page this afternoon: https://x.com/BrandedLegacy

About BioLegacy Evaluative Group, Inc.
BioLegacy Evaluative Group Inc. is a life sciences company dedicated to developing innovative therapies and devices addressing urgent global health challenges. With strategic partnerships at McMaster University and Stanford University, and a newly acquired GMP-compliant manufacturing facility, BioLegacy is positioned to deliver scalable, cost-effective solutions in areas of high unmet need.

About Branded Legacy, Inc.

Branded Legacy, Inc. (OTC:BLEG) is a forward-thinking holdings company dedicated to pioneering solutions in addiction treatment and harm reduction. Through its subsidiary, BioLegacy Evaluative Group, and strategic collaborations with leading institutions like McMaster University and Stanford University, the company drives transformative research and innovation. With a state-of-the-art GMP manufacturing facility in Vancouver, Branded Legacy leverages advanced production capabilities to deliver cutting-edge products, positioning itself as a leader in addressing critical public health challenges. For more information, visit www.brandedlegacy.com.

Investor Relations

Branded Legacy, Inc.
Email: info@brandedlegacy.com
Phone: 877-250-9077

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including projections regarding market growth, revenue potential, and development timelines, are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Branded Legacy undertakes no obligation to update these statements except as required by law.

InvestorWire Service Contact:

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

FAQ

What did Branded Legacy (BLEG) announce on October 27, 2025 about its intranasal device?

Branded Legacy said its subsidiary began engineering a unitary device mold to enable scalable production of an air-driven intranasal delivery system.

How does the September 2025 provisional patent affect BLEG's intranasal device plans?

The company filed a provisional patent in September 2025, which documents the invention but does not constitute an issued patent.

When did Branded Legacy open its GMP-compliant manufacturing facility for BLEG products?

Branded Legacy unveiled a GMP-compliant facility in Vancouver on September 23, 2025 to support manufacturing.

Will the unitary device mold support naloxone distribution for BLEG?

The mold is designed to enable high-volume manufacture of the single-use device intended to deliver therapeutics, including the company’s inhaled naloxone program.

What investor timeline is associated with BLEG's mold development announcement on October 27, 2025?

The company announced initiation of mold engineering on October 27, 2025; no commercial launch date was disclosed.

Does the October 2025 announcement indicate regulatory approval for BLEG's intranasal device?

No regulatory approvals were claimed; the announcement describes engineering, a provisional patent, and manufacturing capability but not regulatory clearance.